Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma

Title
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma
Authors
Keywords
-
Journal
MELANOMA RESEARCH
Volume 27, Issue 4, Pages 342-350
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2017-05-09
DOI
10.1097/cmr.0000000000000353

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search